

## Board of Directors

**14<sup>th</sup> July 2022**

<b>Paper title:</b>	Finance Update Month 2 2022/23	<b>Agenda item</b>  <b>19</b>
<b>Presented by:</b>	Mike Woodhead, Director of Finance, Contracting and Estates	
<b>Prepared by:</b>	Claire Risdon, Deputy Director of Finance	

<b>Purpose of the report</b>		
The purpose of the report is to provide the Trust Board with an overview on the financial performance for M02, for both the Trust and the ICS.	For approval	
	For discussion	<b>X</b>
	For information	

<b>Executive summary</b>		
<b>Trust Financial Performance 2022/23 (Paper 19.1)</b>		
At this early stage in the year, the financial position is looking favourable with a YTD surplus position of £12k which is £250k better than plan. The forecast for the year is a breakeven position which is as planned.		
The key in-year financial risks relate to increased acuity, demand and elevated staff absences which are resulting in higher than expected temporary staffing spend. Work is underway to identify mitigations to manage costs through substantive recruitment.		
The capital position in May is £276k underspent against plan mainly due to delays within Estates Capital Schemes that will be caught up during the year. The forecast capital spend is in line with plan at £4.96m.		
<b>ICS Financial Performance 2022/23 (Paper 19.2)</b>		
The headline position for the ICS for Month 2 and associated risks:		
<ul style="list-style-type: none"> <li>Financial position at Month 2 is adverse variance of £5.1m (£4.2m favourable variance if ESRF recovered).</li> <li>Month 3 will move to a break-even plan, supported by additional funding received into the ICS to support inflationary costs in the baseline plan.</li> <li>Forecast to deliver plan.</li> <li>ICS capital financial position at Month 2 is £1.3m over plan.</li> <li>ICS capital forecast is to deliver plan at Month 2.</li> </ul>		
Do the recommendations in this paper have any impact upon the requirements of the	<b>State below 'Yes' or 'No'</b>	If yes please set out what action has been taken to address this in your paper

protected groups identified by the Equality Act?	<b>No</b>
--	-----------

<b>Recommendation</b>
The Board of Directors is asked to: <ul style="list-style-type: none"> <li>Note the year to date forecast financial position of the Trust and the ICS; and</li> <li>Highlight further assurances required.</li> </ul>

<b>Strategic vision</b>				
Please mark those that apply with an X				
Providing excellent quality services and seamless access	Creating the best place to work	Supporting people to live to their fullest potential	Financial sustainability growth and innovation	Governance and well-led
X	X	X	X	X

<b>Care Quality Commission domains</b>				
Please mark those that apply with an X				
Safe	Effective	Responsive	Caring	Well Led
X	X	X	X	X

<b>Relationship to the Board Assurance Framework (BAF)</b>	The work contained with this report links to the strategic risk(s) as identified in the BAF: <ul style="list-style-type: none"> <li>SO5: To make effective use of our resources to ensure services are environmentally and financially sustainable and resilient (FBIC)</li> </ul>
<b>Links to the Strategic Organisational Risk Register (SORR)</b>	The work contained with this report links to the following corporate risks as identified in the SORR: <ul style="list-style-type: none"> <li>Risk 2536: If we do not make effective use of our resources this may result in regulatory interventions, as well as impacts on quality of services.</li> </ul>
<b>Compliance and regulatory implications</b>	The following compliance and regulatory implications have been identified as a result of the work outlined in this report: <ul style="list-style-type: none"> <li>The NHS Single Oversight Framework requires providers to report performance against national requirements including quality of care, financial performance and sustainability, and delivery of national standards (though some reporting is suspended during the Covid-19 pandemic)</li> </ul>